VIVI — TempraMed Technologies Income Statement
0.000.00%
Last trade - 00:00- CA$93.20m
- CA$99.36m
- $2.26m
Annual income statement for TempraMed Technologies, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS |
| Standards: | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final |
| Revenue | |||
| Total Revenue | 1.8 | 1.68 | 2.26 |
| Cost of Revenue | |||
| Gross Profit | 1.19 | 1.2 | 1.42 |
| Selling / General / Administrative Expenses | |||
| Research And Development | |||
| Depreciation and Amortization | |||
| Total Operating Expenses | 3.04 | 4.88 | 4.53 |
| Operating Profit | -1.25 | -3.2 | -2.27 |
| Total Net Non Operating Interest Income / Expense | |||
| Total Net Non Operating Interest Income / Expense | |||
| Other Net Non Operating Costs | |||
| Net Income Before Taxes | -1.24 | -3.25 | -3.35 |
| Net Income After Taxes | -1.24 | -3.25 | -3.35 |
| Net Income Before Extraordinary Items | |||
| Net Income | -1.24 | -3.25 | -3.35 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||
| Income Available to Common Shareholders Including Extraordinary Items | |||
| Diluted Net Income | -1.24 | -3.25 | -3.35 |
| Diluted Weighted Average Shares | |||
| Basic EPS Including Extraordinary Items | |||
| Diluted EPS Including Extraordinary Items | |||
| Diluted EPS Excluding Extraordinary Items | |||
| Normalised Income Before Taxes | |||
| Normalised Income After Taxes | |||
| Normalised Income Available to Common Shareholders | |||
| Diluted Normalised EPS | -0.016 | -0.042 | -0.043 |